Effect of Opicapone and Levodopa on Daily Motor Patterns in Parkinson’s Disease Patients with Early Motor Fluctuations: Findings from the Korean ADOPTION Study
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus an additional 100 mg dose of levodopa (L-DOPA) on ON-/OFF-daily patterns in patients with…A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease
Objective: To compare efficacy and safety of safinamide and rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease (PD) by matching-adjusted indirect…Motor Phenotype Changes over time in Parkinson’s Disease. A 5-year Follow-up Study
Objective: The objectives of this study are to describe the prevalence of different motor phenotypes (MP) in a cohort of Parkinson’s Disease (PD) patients, to…Developing a selection framework for digital measures of Parkinson’s disease progression for the EJS ACT-PD trial
Objective: To develop a selection process for digital measures (DMs) to include as exploratory outcome measures of Parkinson’s disease (PD) progression in a platform disease…Integrated Clinical Research Intern Program: Impact Upon Recruitment of Participants for Therapeutic Studies Aimed at Parkinson’s Disease (PD) Prevention.
Objective: To discuss the development and benefit of an online internship program created to expand recruitment and retention within a PD cohort and introduce students…Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment
Objective: Evaluate the effect of continuous subcutaneous apomorphine infusion (CSAI) on daily periods of OFF time and Good ON time (ON without troublesome dyskinesia) in…Neuroprotective Effect of Isoquercitrin in Rotenone Induced Parkinson’s Disease-Like Motor and non-motor Symptoms in Zebrafish
Objective: The objective of study is to find out the effect of isoquercitrin, a plant-derived chemical, against Parkinson-like symptoms induced by rotenone in zebrafish.. Background:…Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease
Objective: We recently confirmed that nibrozetone (RRx-001), a Phase 3 small molecule chemoprotective agent, is a direct NLRP3 inhibitor that is CNS permeable. Nibrozetone displays…Continuous Dopaminergic Stimulation-based Levodopa Treatment in Early to Mid-stage Parkinson’s Disease Patients: A Systematic Review and Meta-analysis
Objective: To compare the clinical effectiveness between continuous dopaminergic stimulation (CDS)-based and intermittent levodopa (IL) treatment in patients with early to mid-stage Parkinson’s disease (PD).…Comparing the Selected Device-Aided Therapy of Movement Disorder Specialist Team with Patient Selections
Objective: This study aims to compare the decision made by patients and physicians in selecting device-aided therapy (DAT) for advanced Parkinson’s disease (aPD) and to…
- « Previous Page
- 1
- …
- 172
- 173
- 174
- 175
- 176
- …
- 181
- Next Page »